E
Elisa de Stanchina
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 268
Citations - 26387
Elisa de Stanchina is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 65, co-authored 201 publications receiving 21076 citations. Previous affiliations of Elisa de Stanchina include Kettering University & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
A microRNA component of the p53 tumour suppressor network
Lin He,Xingyue He,Xingyue He,Lee P. Lim,Elisa de Stanchina,Elisa de Stanchina,Zhenyu Xuan,Yu Liang,Wen Xue,Lars Zender,Jill F. Magnus,Dana Ridzon,Aimee L. Jackson,Peter S. Linsley,Caifu Chen,Scott W. Lowe,Michele A. Cleary,Gregory J. Hannon +17 more
TL;DR: A family of miRNAs, miR-34a–c, whose expression reflected p53 status is described, whose encoded genes are direct transcriptional targets of p53, whose induction by DNA damage and oncogenic stress depends on p53 both in vitro and in vivo.
Journal ArticleDOI
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.
Hans-Guido Wendel,Elisa de Stanchina,Jordan S. Fridman,Jordan S. Fridman,Abba Malina,Sagarika Ray,Scott C. Kogan,Carlos Cordon-Cardo,Jerry Pelletier,Scott W. Lowe +9 more
TL;DR: It is shown that Akt promotes tumorigenesis and drug resistance by disrupting apoptosis, and that disruption of Akt signalling using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but not in those with other apoptotic defects.
Journal ArticleDOI
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
TL;DR: It is found that the splicing factor SF2/ASF is upregulated in various human tumors, in part due to amplification of its gene, SFRS1, and can act as an oncoprotein and is a potential target for cancer therapy.
Journal ArticleDOI
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
Ping Mu,Zeda Zhang,Matteo Benelli,Wouter R. Karthaus,Elizabeth Hoover,Chi-Chao Chen,Chi-Chao Chen,John Wongvipat,Sheng-Yu Ku,Dong Gao,Zhen Cao,Zhen Cao,Neel Shah,Elizabeth J. Adams,Wassim Abida,Philip A. Watson,Davide Prandi,Chun-Hao Huang,Chun-Hao Huang,Elisa de Stanchina,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Leigh Ellis,Himisha Beltran,Himisha Beltran,Mark A. Rubin,Mark A. Rubin,David W. Goodrich,Francesca Demichelis,Francesca Demichelis,Charles L. Sawyers,Charles L. Sawyers +32 more
TL;DR: In vitro and in vivo human prostate cancer models are used to show that these tumors can develop resistance to the antiandrogen drug enzalutamide by a phenotypic shift from androgen receptor–dependent luminal epithelial cells to AR-independent basal-like cells.
Journal ArticleDOI
E1A signaling to p53 involves the p19(ARF) tumor suppressor.
Elisa de Stanchina,Mila E. McCurrach,Frederique Zindy,Sheau-Yann Shieh,Gerardo Ferbeyre,Andrew V. Samuelson,Carol Prives,Martine F. Roussel,Charles J. Sherr,Scott W. Lowe +9 more
TL;DR: Reintroduction of p19(ARF) functions as part of a p53-dependent failsafe mechanism to counter uncontrolled proliferation and may contribute to E1A's ability to enhance radio- and chemosensitivity.